Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings [Seeking Alpha]
Biogen Inc. (BIIB)
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
biogen.com/en_us/investors.html
Company Research
Source: Seeking Alpha
The company's stock price has fluctuated, reaching highs of over $350 per share but falling to lows of under $200 per share recently. Biogen's new CEO, Chris Viehbacher, has implemented a cost savings program to address profitability issues and focus on operational execution. Alzheimer's drug Leqembi has overcome controversy to win full approval and is growing revenues - this trend can help support growth in Biogen's share price - and perhaps a return to $300 per share. Investment Overview: Brief History Of Biogen Since 2019 - Declining MS Sales, Alzheimer's Struggles Biogen Inc. NASDAQ: BIIB ) - the Cambridge, Massachusetts headquartered, neurological and neurodegenerative disease treatment specialist - has had a tumultuous few years, characterized by moments of extreme optimism, followed by lengthy periods of disappointment. Biogen's main source of income for many years has been its multiple sclerosis ("MS") franchise - in 2019, its dimethyl fumarate drug Tecfidera earned
Show less
Read more
Impact Snapshot
Event Time:
BIIB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIIB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
News
- Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $340.00 price target on the stock.MarketBeat
- Multiple Sclerosis Drugs Market Outlook 2024-2028, 2033 - A $48 Billion Global Opportunity Dominated by Biogen, Novartis, Roche, Bayer HealthCare, and Pfizer [Yahoo! Finance]Yahoo! Finance
- Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis [Yahoo! Finance]Yahoo! Finance
- Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisGlobeNewswire
BIIB
Earnings
- 4/25/24 - Beat
BIIB
Sec Filings
- 5/3/24 - Form 4
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- BIIB's page on the SEC website